Clinical Medicine News
-
Candida auris and Infection Control Resources for Healthcare Facilities in Puerto Rico
Several years ago, the Centers for Disease Control and Prevention (CDC) announced it was establishing the Antibiotic Resistance Laboratory Network (AR Lab Network) in Puerto Rico and all 50 states. It was designed to help detect new forms of drug resistance as novel fungal threats emerge. Specifically mentioned in the announcement was Candida auris. CDC reported that this fungus poses a unique ...
-
ReShape Lifesciences Announces 2017 Weight Loss Contest Winner
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced the winners of its 2017 weight loss contest, which recognizes patients for their successful weight loss with the ReShape Balloon™. The contest winner lost a total of 80 pounds, or 41% total weight loss (TWL), with 60 pounds, or 28% TWL, lost ...
-
Former Roche Diagnostics NAM CEO Michael Tillmann joins X-ZELL executive board
X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board. Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO position at Roche Diagnostics North America and Asia Pacific. Between 2006 and 2010, he also served as a member of the company’s global executive ...
By X-Zell Inc.
-
ReShape Lifesciences Receives FDA 510(k) Clearance for the GIBI HD Calibration Tubes for use in Gastric and Bariatric Procedures
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced ...
-
CCRO Conducts First Clinical Trial with Head and Neck Surgery
Jeremy Richmon, MD is leading a new clinical trial sponsored by Alume, the Center for Clinical Research Operations' (CCRO) first clinical trial with Head and Neck Surgery. The trial involves using a tracer to help identify nerves intraoperatively. This type of cutting edge translational surgical innovation improves outcomes and ultimately the lives of our patients. The amount of coordination and ...
-
Caldera Medical Announces FDA Clearance for New Desara TVez for Stress Urinary Incontinence
Caldera Medical, a medical device company that develops best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and Polyps announced the launch of Desara® TVez, an expansion to their Desara® Family of products. “Staying true to our commitment of being surgeon and patient focused, Caldera Medical collaborated with dozens of leading ...
-
Who can benefit from an adjustable gastric band implant?
Who can benefit from an adjustable gastric band implant? Adults between the ages of 18 and 60 years with morbid obesity (BMI of > 40) or severe obesity (BMI of > 35) with at least one complication (diabetes, hypertension, sleep apnea syndrome, joint disorders) People who have already tried to lose weight without success despite receiving specialized medical care for several months ...
-
Buy-out of the Helioscopie company by the Santé Actions group
On October 26, 2010, Helioscopie, an expert company in medical implants in the obesity field located in Vienne, France (38), came under new direction. The Santé Actions group took control of the company. Dr. Sauveur Ferrara will hold the office of President. Dr. Ferrara, the President and founder of the Santé Actions group, a company specialized in health and medico-social care, is ...
-
CD Formulation Offers Insights, Strategies, and Practical Suggestions on Pre-formulation Studies for Pharmaceuticals
In a recent statement, the US-based CRO company CD Formulation re-demonstrated its competence in drug development and announced that it now offers industry-leading insights, strategies, and practical suggestions on pre-formulation studies for drug developers worldwide. The past decade has witnessed a boom of new chemical entities development in the hope of bringing more therapies to diseases hard ...
-
Reflections from 4D Path’s HER2 and Ki67 Publications
4D Path recently had the honor of including two publications in the virtual curriculum at the 2022 ASCO Annual Meeting. The publications addressed that the majority of druggable targets that drive oncogenic vulnerability are not expressed in a uniform or homogeneous manner throughout tumor tissue. Thus, intratumoral heterogeneity, as observed among the cells of an individual ...
By 4D Path Inc.
-
Does velashape really work for cellulite
Cellulite is a change that occurs in most adults, whether they are thin or overweight. Although we know little about what causes cellulite, it can create a dimpled or uneven surface of the skin. Unfortunately, cellulite can only become more visible with age. While there is nothing you can do to reduce cellulite on your own, VelaShape uses radiofrequency energy to stimulate collagen growth and ...
-
Alfa Chemistry Launches Thiophenes as Heterocyclic Organic Compounds for Academic Research and Industrial Manufacturing
Extensively existing in nature, heterocyclic organic compounds are of paramount importance in medicinal chemistry, the discovery of novel drugs in particular. Fully aware of the market demand for such chemicals, Alfa Chemistry recently announced the launch of thiophenes, a type of heterocyclic compound comprehensively ranged for scientists and researchers worldwide dedicated to exploring the ...
-
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised ...
By IN8Bio Inc.
-
miR Scientific launches "Can do Blue" on September 1, 2022, as Prostate Cancer Awareness Month
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
-
Microbot Medical to Present the Self-Cleaning Shunt at the 16th Asian Australasian Congress of Neurological Surgeons
HINGHAM, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it will be presenting the Company’s Self-Cleaning Shunt (SCS) at the 16th Asian Australasian Congress of Neurological Surgeons (AACNS). The AACNS is hosted by the Israel Neurosurgery Society and is being held from September 6th – 8th in Jerusalem, Israel. Dr Gustavo Rajz, Head of ...
-
Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion
Confluent Medical Technologies (Confluent), today announced the Grand Opening of the latest addition to their large scale manufacturing center of excellence in Alajuela, Costa Rica expanding their capacity for Nitinol processing and catheter manufacturing. This new facility will be co-located with the existing Confluent Costa Rica facility and will add an additional 66,000 square feet to this ...
-
Eagle Genomics to exhibit as Microsoft Digital Innovation Partner?at ACHEMA 2022
Today, Eagle Genomics, the software platform business pioneering the application of network science to biology,?announced its attendance at international tradeshow ACHEMA 2022 in Frankfurt, Germany next week (22-26 August) as a Microsoft Showcase Partner. Eagle Genomics will be featured in Microsoft’s ‘Digital Hub’ Innovation space under the theme “Eagle Genomics and ...
-
Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...
-
Inversago Pharma to present preclinical data on INV-101 in Idiopathic Pulmonary Fibrosis at the ERS Congress 2022
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announces the presentation of preclinical data at the 2022 Congress of the European Respiratory Society (ERS), to be held in Barcelona, Spain and online. Abstract: “INV-101, a cannabinoid receptor-1 inverse agonist, reduces fibrosis in a bleomycin mouse model ...
-
Do You Know The Difference Between SHR And IPL
IPL stands for Intense Pulse Light, light emitted is absorbed by the hair pigment and changed into heat to damage the targeted hair follicle. IPL technology is not suitable for treating sensitive and/or darker skin types. SHR stands for Super Hair Removal, the latest pain free advancement in Laser/IPL permanent hair removal systems. With SHR technology, only 50 per cent of the energy targets the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you